OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation

OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value CreationCompletion of Tedopi’s phase 3 in Non-Small ...

Viking Therapeutics: Prepping For A Critical 2026

Viking Therapeutics advances oral and injectable VK2735 for obesity with strong cash, pipeline depth, and key 2026 catalysts.
Business Wire

European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsimaâ„¢ IV (intravenous) liquid formulation, the world ...